TriSalus Life Sciences (TLSI) Net Cash Flow (2021 - 2026)

TriSalus Life Sciences' Net Cash Flow history runs 6 years deep, the most recent figure standing at $35.8 million for Q1 2026.

• On a quarterly basis, Net Cash Flow rose 699.2% year-over-year to $35.8 million in Q1 2026; TTM through Mar 2026 was $43.2 million, a 378.44% increase from a year earlier, with the FY2025 full-year figure at $11.9 million, up 466.36% from the prior year.
• Net Cash Flow advanced to $35.8 million in Q1 2026 per TLSI's latest filing, from -$2.2 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $35.8 million in Q1 2026 and bottomed at -$17.8 million in Q3 2022.
• The 5-year median for Net Cash Flow is -$2.6 million (2023), against an average of $1.5 million.
• Across the five-year window, Net Cash Flow slumped 15785.95% in 2023 and soared 699.2% in 2026, its largest moves.
• Year by year, Net Cash Flow stood at -$2.7 million in 2022, then tumbled by 255.5% to -$9.5 million in 2023, then surged by 70.93% to -$2.8 million in 2024, then advanced by 18.64% to -$2.2 million in 2025, then soared by 1690.93% to $35.8 million in 2026.
• Per Business Quant, the three latest TLSI Net Cash Flow figures stand at $35.8 million (Q1 2026), -$2.2 million (Q4 2025), and -$3.8 million (Q3 2025).